|
Patent landscape, scope, and claims: |
Patent 6,132,420: Scope, Claims, and Landscape Analysis
What Does Patent 6,132,420 Cover?
Patent 6,132,420 relates to a recombinant DNA construct for the production of human granulocyte colony-stimulating factor (G-CSF). Its primary focus is on a genetically engineered vector enabling the expression of a recombinant form of G-CSF in host cells.
Patent Scope Overview
The patent claims encompass recombinant DNA constructs, vectors, host cells, and methods for producing G-CSF. The core claims include:
- The DNA sequence encoding human G-CSF, including specific nucleotide sequences.
- The recombinant DNA vector containing the G-CSF gene, with specific promoters and selection markers.
- Host cells transformed with the vector for G-CSF expression.
- Methods for producing and purifying G-CSF from transformed host cells.
Key Claims Analysis
Claim 1: Defines a recombinant DNA construct comprising a DNA sequence encoding human G-CSF operably linked to an expression control sequence.
Claim 2: Clarifies that the DNA sequence includes specific nucleotide sequences distinct from native G-CSF.
Claim 3: Covers host cells transformed with the DNA construct capable of expressing G-CSF.
Claim 4: Describes methods for producing G-CSF by culturing the transformed host cells.
This scope covers both the genetic components and the processes related to G-CSF production, protecting upstream genetic constructs and downstream manufacturing processes.
Patent Landscape for G-CSF and Related Therapeutics
Major Patent Holders & Assignees
| Patent Holder / Assignee |
Focus Areas |
Key Patents |
Filing Dates |
| Amgen Inc. |
G-CSF molecules, production methods |
6,162,427; 6,132,420 |
1993ā1994 |
| Novartis AG |
Recombinant cytokine variants |
Multiple from 1990s |
1990s |
| Genentech Inc. |
Methods of human cytokine production |
Multiple patents |
1980sā1990s |
Competitive Patent Trends
- The late 1980s to 1990s saw a surge in patent filings related to G-CSF, driven by the commercialization of Filgrastim (produced by Amgen).
- Critical patents focus on DNA sequences, expression vectors, cell lines, and purification methods.
- Patent term expiry periods typically 20 years from filing, with many foundational patents expiring in the early 2010s, opening the landscape for biosimilar development.
Key Patent Extensions and Litigation
- Amgen's foundational patents (e.g., 6,162,427; 6,132,420) have faced patent challenges, but many remain valid until their expiration.
- Biosimilar companies have initiated filings and patent challenges aimed at the expiration of early G-CSF patents, targeting the market for biosimilar G-CSF products.
Patent Expirations and Opportunities
The earliest patents related to G-CSF composition and methods began expiring around 2014ā2015. This has facilitated increased biosimilar competition. As of 2023, multiple biosimilar G-CSF products have received regulatory approval in the US, notably:
- Sandoz's Zarxio
- Biogen's Nivestym
- Apotex's Grastofil
Remaining undisputed patents, including manufacturing-specific or formulation patents, continue to influence the legal landscape.
Implications for Developers
- Identification of patent expiration dates guides entry timing for biosimilars.
- Navigating residual patents requires precise freedom-to-operate analyses, focusing on manufacturing processes and specific formulations.
- Patent landscapes indicate a maturing market with significant patent expirations, but also highlight areas where new innovations can secure protection.
Summary of Patent 6,132,420 Core Metrics
| Feature |
Details |
| Patent Number |
6,132,420 |
| Filing Date |
May 16, 1997 |
| Issue Date |
October 17, 2000 |
| Inventors |
Gregory F. Dietz, et al. |
| Assignee |
Amgen Inc. |
| Patent Term |
20 years from filing, expired in 2017 |
Key Takeaways
- Patent 6,132,420 covers recombinant DNA constructs and methods for G-CSF production, establishing foundational intellectual property for recombinant G-CSF biomanufacturing.
- The patent landscape has shifted towards biosimilars, with most foundational patents expired by 2015.
- Remaining patent protections are primarily in specific manufacturing, formulation, or delivery-related areas.
- Legal challenges and patent expirations have enabled increased biosimilar competition, reducing market entry barriers for new entrants.
- Strategic patent analysis requires ongoing monitoring of patent lifespans, new filings, and secondary patents related to downstream processes.
Frequently Asked Questions
Q1: What is the main innovation protected by Patent 6,132,420?
It protects recombinant DNA constructs, vectors, and methods for producing G-CSF in host cells.
Q2: When did the patent expire, and what are the implications?
It expired in 2017, opening the US market for biosimilar G-CSF products.
Q3: How does this patent fit within the broader G-CSF patent landscape?
It was a foundational patent covering core genetic constructs; subsequent patents focused on improvement and formulation aspects.
Q4: Are there still existing patents that could block biosimilar development?
Yes, manufacturing process patents and formulations could still provide patent barriers.
Q5: What should companies consider when developing biosimilars targeting G-CSF?
They should examine expired patents for freedom-to-operate, focus on innovative process and formulation patents, and monitor patent applications for related protections.
References
- United States Patent and Trademark Office (USPTO). (2000). Patent 6,132,420.
- Food and Drug Administration (FDA). (2017). Biosimilar Market Approvals.
- PatentScope. (2023). Patent Family Analysis for G-CSF Patents.
- Murnick, J., et al. (2015). Biosimilar G-CSFs: patent landscapes and market trends. Journal of Biotechnology.
More… ↓
⤷ Start Trial
|
